← Global Bio-chem Technology Group Co. Ltd / ADR (GBCMY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Global Bio-chem Technology Group Co. Ltd / ADR (GBCMY)
Biotechnology · market cap $139M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Global Bio-chem Technology Group Co. Ltd (GBCMY) is a biotechnology company with approximately 1,890 employees and a market capitalization of roughly $139 million. Its lead asset is fezolinetant, currently in Phase 3 development for vasomotor symptoms (hot flashes), with two additional Phase 2 assets — gilteritinib in AML and enzalutamide in HER2-amplified indications. No upcoming catalysts are on the public calendar, and no financial details (cash, runway, revenue) have been disclosed in the provided data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Gilteritinib | Phase 2 | Acute Myeloid Leukemia (AML) |
| Fezolinetant | Phase 3 | Hot Flashes |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GBCMY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.